<i>PTPN11</i> mutations Confer Adverse Outcomes and Therapy Resistance in Older Patients with Acute Myeloid Leukemia (AML)
Dennis Lee, Justin D. Kaner(NewYork–Presbyterian Hospital), Michael Kluk(Cornell University), Kata Alilovic(Cornell University), Michael R. Savona(Vanderbilt University), Michael S. Samuel(Cancer Research UK Scotland Institute), Nuria Mencia Trinchant(NewYork–Presbyterian Hospital), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Brianna N. Smith(Vanderbilt University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Eti Sinha(Stanford University), Gail J. Roboz(Cornell University), Jorge Contreras(NewYork–Presbyterian Hospital), Tyler Augi(University of Pittsburgh)
Cited by 4
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k